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Protein inhibitors provide a physiological mechanism of regulation of proteolytic enzymes. While most 
single-domain inhibitors have one reactive site with which they target peptidases of a specific catalytic 
class, selected specimens inhibit two peptidase molecules simultaneously, thus giving rise to ternary 
complexes. To study such inhibition, we analyzed the function of one of these proteins, sermetstatin, 
which strongly binds as a dimer to serine proteinases (SPs) and a metallopeptidase (MP). In addition, we 10 
determined the structures of the isolated inhibitor dimer and its heterotetrameric complexes with the SP 
subtilisin and the MP snapalysin, which reveal that inhibition occurs through two independent distal 
reactive sites. These structures and the derived model for the heterohexameric complex provide for the 
first time a detailed view of the molecular mechanism of simultaneous inhibition of proteinases belonging 
to two distinct mechanistic classes by a single-domain protein. 15 
Introduction 
Due to the essentially irreversible nature of peptide-bond 
hydrolysis, proteolytic enzymes must be tightly regulated to 
prevent spatially and temporally deleterious activity. One such 
regulatory mechanism is provided by co-localizing protein 20 
inhibitors which mostly target one or several peptidases of a 
certain catalytic class through a single inhibitory region by 
blocking the active-site cleft of the enzyme 1, 2. A special case is 
provided by inhibitors with two inhibitory sites which mimic the 
head architecture of the Roman god Janus and are capable of 25 
inhibiting two peptidase molecules simultaneously 3. Such Janus-
faced inhibitors (see Suppl. Table S1) are infrequent among the 
plethora of inhibitors described, and none of them has yet been 
structurally characterized in a ternary complex with two different 
targets.  30 
To address this question, we focused on the bacterial genus 
Streptomyces, which occurs in soil and aquatic habitats and is the 
source of many medicinal, pharmaceutical, and industrial 
products of natural origin such as antibiotics 4. These bacteria 
secrete a number of peptidases and cognate protein inhibitors 35 
thought to participate in morphological development and defense 
against extrinsic proteinases. Among these inhibitors are 
members of family I16 (according to MEROPS inhibitor 
database, http://merops.sanger.ac.uk; 5), which only occur within 
the bacterial order Actinomycetales. These inhibitors generally 40 
target serine proteinases (SPs) of the chymotrypsin- and 
subtilisin-type; some also bind tightly to Streptomyces griseus 
griselysin but apparently not the structural and functional relative 
thermolysin from Bacillus thermoproteolyticus, which is in 
MEROPS metallopeptidase (MP) family M4 5. This inhibition is 45 
exerted by the same region employed for SPs 6, so that, although 
they are bi-functional, dual inhibition cannot occur 
simultaneously. Previously studied I16 inhibitors include 
Streptomyces subtilisin inhibitor (SSI) from Streptomyces 
albogriseolus, plasminostreptin from Streptomyces 50 
antifibrinolyticus, alkaline protease inhibitor API-2c’ from 
Streptomyces pseudogriseolus, and trypsin inhibitor STI2 from 
Streptomyces longisporus 5, 7-11 (see Fig. 1a). Among them is also 
sermetstatin—also known as Streptomyces caespitosus neutral 
proteinase inhibitor 8—, which is a 113-residue secreted single-55 
domain molecule and the main object of study of the present 
work. 
Inhibitory profile of sermetstatin 
We produced sermetstatin by recombinant overexpression in 
Escherichia coli (see Experimental procedures in the Electronic 60 
Supplementary Information [ESI]) and found it to be a 
homodimer in solution, thus confirming earlier results 8. We 
assessed its inhibitory function, which had been previously ruled 
out for the cysteine proteinase cathepsin B and the aspartic 
proteinase pepsin 8, against a broad panel of model peptidases 65 
(Suppl. Table S2). To this end, we recombinantly produced and 
purified the MP snapalysin from S. caespitosus, which is a 
member of the metzincin clan of MPs—unrelated to griselysin 
and other M4 peptidases 12-14. We found it is potently inhibited by 
sermetstatin with an apparent Ki of 6nM, which is consistent with 70 
reported results 8. These inhibition studies were complemented by 
autolytic activation studies with recombinant wild-type 
prosnapalysin from Streptomyces coelicolor (the sequence of the 
propeptide of the S. caespitosus zymogen is not known). We 
found the zymogen underwent autolytic activation in vitro at the 75 
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concentration resulting from the purification strategy so fast that 
the intact zymogen could actually not be isolated. This cleavage 
also removed the N-terminal fusion protein employed for 
purification. Two initial cleavages were observed at bonds F59-5 
F60 and G212-F213 (S. coelicolor prosnapalysin numbering in 
regular characters; see UniProt sequence database access code 
P0A3Z7), which removed not only the N-terminal part but also a 
15-residue C-terminal fragment, as previously described for the 
MP ulilysin from Methanosarcina acetivorans 15. Subsequently, 10 
several cleavages occurred in the remaining part of the 49-residue 
propeptide to finally yield the mature 133-residue form spanning 
residues A80-G212. Consistent with an autolytic mechanism in 
vitro, mutant E164A, which affects the glutamate that plays the 
role of a general base/acid in the catalytic process in MPs 12, 16, 17, 15 
displays only very slow activation over a period of weeks. In 
nature, however, prosnapalysin activation is likely to occur under 
assistance of other proteinases. 
 Further to snapalysin, sermetstatin did not inhibit any other 
MP assayed, which included thermolysin and metzincins of the 20 
astacin, pappalysin, serralysin, fragilysin, ADAM/adamalysin and 
matrix metalloproteinase families. Taken together with previous 
results showing no inhibition of the M4-family MPs 
Pseudomonas aeruginosa elastase and vimelysin, as well as the 
unassigned MP almelysin 8, we conclude that sermetstatin is most 25 
likely a specific inhibitor of snapalysins through one of its Janus 
faces. In addition, sermetstatin potently inhibited subtilisin 
Carlsberg from Bacillus licheniformis (with an apparent Ki of 
1.3nM) and proteinase K (Suppl. Table S2), as well as subtilisin 
BPN’ from Bacillus amyloliquefaciens 8, all of them peptidases of 30 
biotechnological relevance. However, it only moderately 
inhibited chymotrypsin and elastase, and only weakly targeted 
trypsin (Suppl. Table S2). These results confirm 
that sermetstatin is a potent, though rather broad-
spectrum inhibitor of subtilisin-type—and, 35 
partially, chymotrypsin-type— SPs through its 
other Janus face. 
Structure of sermetstatin 
We crystallized and solved the structure of 
sermetstatin by single-wavelength anomalous 40 
diffraction with the help of a selenomethione 
derivative (see ESI and Suppl. Table S3). The 
protein is an elongated α/β-sandwich of maximal 
dimensions 45x30x25Å. It consists of a five-
stranded antiparallel β-sheet (β3-β2-β1-β4−β5; 45 
connectivity -1,-1,+3,+1) twisted by ~30º, whose 
concave face accommodates two α-helices (α1 
and α2) and a 310-helix (η1; see Figs. 1a and 2a). 
The overall structure is tethered by a large 
hydrophobic core provided by side chains of the 50 
β-sheet on its concave face, the two α-helices, 
and the C-terminal tail. The structure is further 
maintained by two disulfide bonds. The first (C31-
C46; sermetstatin mature-protein residues 
numbered in superscript; see Fig. 1a and subtract 55 
28 from UniProt Q9FDS0 numbers) links the first 
“scaffold helix” α1 with β2 and the subsequent 
loop connecting strands β2 with β3 (Lβ2β3), 
which includes the “reactive-site loop 1” (C31-
A35). The second disulfide bond (C69-C99) 60 
connects the second “scaffold helix” α2 with 
Lα2β4, which contains the “reactive-site loop 2” (P65-F73). Both 
reactive-site loops protrude from the molecular surface and are 
fully solvent accessible (Fig. 2a). The C-terminal carboxylate is 
anchored to the side chain of R25 within β2; by contrast, the N-65 
terminus loosely protrudes from the molecular surface and 
becomes only rigid at P5, which leads to the first residue of strand 
β1.  
Two sermetstatin molecules intimately associate through the 
convex faces of their β-sheets to yield a crystallographically-70 
related dimer (Fig. 2a), in agreement with the oligomeric state 
found in solution. The sheet planes are rotated by ~35º away from 
each other and the interaction surface spans ~800Å2, viz. 25% of 
the total surface of a monomer. The interaction is mainly 
hydrophobic and made by 31 close contacts, which include 75 
symmetric hydrophobic interactions between ten residues 
provided by each sheet of either monomer, and only two salt 
bridges between R88 of one protein chain and D81 of the other. 
Structure similarity searches with sermetstatin against the 
Protein Data Bank (PDB) only identified the I16-family relative 80 
SSI, which is also a dimer, as being closely related. However, 
significant variations, in particular around reactive-site loop 2, the 
scaffold helices and the linking disulfide bonds, and, most 
importantly, the N-terminal segment—which is longer, differs in 
sequence (Fig. 1a), and is disordered until positions 4-7 in the 85 
different wild-type SSI structures reported (PDB access codes 
3SSI 18, 2SIC 19, and 2TLD 20)—account for functional 
differences (see below). Consistently, the sermetstatin structure 
could not be solved by Patterson-search techniques using SSI as 
search model (see ESI and Fig. 1b). In addition to SSI, the 90 
isolated structure of plasminostreptin has been reported 21 but the 
coordinates are not available. 
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Structure of the subtilisin: sermetstatin complex 
The crystal structure of the complex between subtilisin 
Carlsberg and sermetstatin was determined by Patterson search 
and reveals a 2+2 heterotetramer as 5 
anticipated by studies in solution, with a 
central non-cleaved inhibitor dimer—as 
present in the unbound structure—and one 
enzyme moiety bound to each inhibitor 
monomer (Fig. 2b and Suppl. Table S3). 10 
Only two segments of sermetstatin adopt a 
different conformation from the unbound 
structure: the flexible N-terminal segment 
until A7, and the segment preceding and 
including reactive-site loop 2 until C69. The 15 
latter variation is due to the flip of the 
peptide bond L60-A61. The only 
enzyme:inhibitor interaction is precisely 
made by reactive-site loop 2, adequately 
positioned by its scaffold helix, and the 20 
active-site cleft of the enzyme (Fig. 3a). 
The loop, which includes the reactive-site 
bond M71-Y72, is inserted wedge-like 
mimicking a substrate in extended, 
“canonical” conformation in the active-site 25 
cleft of the enzyme following the “standard 
mechanism” of inhibition, terms which 
were coined by Laskowski, Bode, Huber, 
and others 1, 2, 22. This mechanism has only 
been structurally proven to date for SP 30 
inhibitors in general and for the specific 
insect metalloproteinase inhibitor of 
thermolysin-family MPs 23. Rigidity to 
reactive-site loop 2 is conferred by the 
proline at position P2 (active-site cleft and 35 
substrate sub-site nomenclature according 
to 17, 24 in bold) and by disulfide bond C69-
C99. On the non-primed side of the 
subtilisin cleft, the inhibitor main chain is 
anchored via a β-ribbon interaction to 40 
segment G100-Y104 (subtilisin mature-
protein residue numbering in subscript; 
subtract 104 from UniProt P00780 
numbers), which creates an upper rim of the 
cleft, through three hydrogen bonds. Below 45 
the cleft, subtilisin segment S125-G128 
further tethers the inhibitor through three 
more inter-main-chain hydrogen bonds. V68 
and M71, respectively, occupy the two sub-
sites of the active-site cleft important for 50 
specificity in subtilisin, S4 and S1 25. The 
catalytic serine, S221, hydrogen bonds 
through its Oγ atom the inhibitor at M71 N 
and, downstream of P1, the polypeptide 
undergoes a kink that probably prevents 55 
cleavage at M71-Y72 and results in the main 
chain at the two subsequent residues being 
hydrogen-bonded in an antiparallel manner 
by N318-T220. Contrary to MPs, substrate 
position P1’ is not important for specificity 60 
in SPs in general, and Y72 points toward 
bulk solvent; F73 in P3’, by contrast, 
approaches the enzyme and performs a 
stacking interaction with F189 (Fig. 3a). The small interacting 
surface between enzyme and inhibitor—despite high inhibitory 65 
potency (see above)—means that upon superposition of the 
proteinase moieties of the two complexes within the 
heterotetramer, the inhibitor moieties display a relative rotation of 
~10º around an axis horizontally traversing the active-site cleft  
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(Fig. 3b). In addition, it also explains why several SPs are 
targeted by the inhibitor, as no exosites are employed for binding 
that could confer specificity. Finally, superposition of the 
complex with the one reported between SSI and subtilisin BPN’ 5 
(PDB 2SIC; 19) reveals very similar binding. As observed in the 
asymmetric unit of the subtilisin:sermetstatin structure, a relative 
reorientation between the sermetstatin and SSI inhibitor 
moieties—here of ~20º—is found upon superposition of the 
respective enzyme parts (Fig. 3c). 10 
Redesign of inhibitory specificity 
Inhibitory studies with wild-type sermetstatin revealed only 
weak activity against trypsin (Suppl. Table S2 and 8), possibly 
owing to the presence of a methionine in P1 (M71). In order to 
design a better inhibitor of the latter SP, we produced a mutant, 15 
M71K, to match the specificity of trypsin. While this mutant did 
not have any influence on the MPs tested, it showed a twofold 
increase in trypsin inhibition and a substantial decrease in the 
inhibition of hydrophobic S1-specific SPs of subtilisin type 
(subtilisin Carlsberg and proteinase K) and chymotrypsin type 20 
(chymotrypsin and elastase), i.e. we were able to alter the 
specificity of sermetstatin. In addition, we also replaced positions 
P1’ and P2’ of sermetstatin with the residues found in SSI 
(mutant Y72V+F73Y; see Fig. 1a) to assess the importance of 
these sites but could not observe any significant inhibitory 25 
difference with the wild-type (Suppl. Table S2). 
Structure of the snapalysin: sermetstatin complex 
The crystal structure of the complex between S. caespitosus 
snapalysin and sermetstatin was determined by multi-step 
Patterson search and also shows a heterotetrameric 2+2 30 
quaternary structure (Fig. 2c and Suppl. Table S3), again in 
accordance with results in solution. Three such structurally-
equivalent heterotetramers totaling 12 
protein chains (A-L) were found in the 
crystal asymmetric unit, and the 35 
discussion hereafter is centered on 
tetramer ABCD (see ESI). The 
structure of the central dimeric 
sermetstatin core shows an intact 
inhibitor and almost exactly the same 40 
minor structural deviations from the 
unbound structure as seen in the 
subtilisin complex. However, unlike the 
unbound structure and the latter 
complex, reactive-site loop 2 is flexible 45 
and partially disordered in some of the 
polypeptide chains. Snapalysin, in turn, 
is in a virtually identical conformation 
to the unbound structure (PDB 1KUH; 
26) throughout its entire structure except 50 
for loop A36-A40 (italicized S. 
caespiosus snapalysin residues and 
subscript numbers according to the 
mature MP sequence; see UniProt 
P56406), which is distal from the 55 
active-site cleft and thus the zone of 
interaction with sermetstatin. Within 
the complex, the proteinase is bound by 
a region on the opposite surface to the 
subtilisin binding site (Fig. 2c) through 60 
a large surface contributed to by several 
protein segments. This results in little 
flexibility at the inter-protein junction as seen upon superposition 
of the distinct complexes. The interaction between snapalysin 
(chain A) and sermetstatin (chain B) buries an interface of 65 
~870Å2 (~13% of the total surface of both enzyme and inhibitor). 
It includes 43 close contacts, among them 11 hydrogen bonds, 
and hydrophobic interactions between eight peptidase and seven 
inhibitor residues. Segments involved include the N-terminal tail 
(S1-P5), reactive-site loop 1, helix α1 (at R43-N50), and Lβ4β5 (at 70 
N85-G86) of the inhibitor; and R51-D58, Q71-Y75, R79-H87, D93-G97, 
and G105-P108 of the proteinase moiety. This implies that not only 
the active-site cleft is targeted during inhibition but also exosites 
on the protease surface, and this, in turn, explains the specificity 
of this second Janus face for snapalysin.  75 
The present inhibition modus follows a novel mechanism for 
MP inhibitors: the N-terminal segment is inserted in a substrate-
like manner in canonical conformation into the non-primed side 
of the active-site cleft, thus establishing a β-ribbon-type 
interaction with the β-strand above the active-site cleft at A55-D58 80 
(see Fig. 4). The side chain of H3 is directed toward the peptidase 
moiety and approaches the zinc-bound catalytic solvent through a 
solvent bridge. To assess this interaction, we constructed two 
point mutants, H3R and H3E, which showed inhibitory activity 
indistinguishable from that of the wild type (data not shown), 85 
which is logical as the structure should be able to accommodate 
both changes simply through removal of the bridging solvent. 
The second main interacting region for inhibition between 
snapalysin and sermetstatin is provided by reactive-site loop 1, 
which penetrates cleft sub-site S1’ with Y33, thus matching the 90 
substrate specificity of the MP 26, 27 (Fig. 4). The aromatic side 
chain approaches R79, which creates the bottom of the 
hydrophobic S1’ pocket of the enzyme through the aliphatic part 
of its side chain. Due to the intrusion of reactive-site loop 1, Y95, 
which is in a position indistinguishable from that seen in the 95 
unbound structure 26 and is generally supposed to stabilize the  
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tetrahedral reaction intermediate during catalysis 12, contacts the 
main-chain carbonyl of the loop at A32 through its side chain. To 
assess the importance of this loop in vitro, we constructed a 
double point mutant, Y33P+T34G, which mimics the sequence of 
SSI at this site (Fig. 1a), and found only residual inhibitory 5 
activity against snapalysin, while the behavior against SPs was 
unaltered (Suppl. Table S2). This supports an authentic key role 
in inhibition for this second Janus-face site, which is absent in 
SSI and, most likely, other I16 inhibitors studied, which are 
evolutionarily more distant from sermetstatin than from each 10 
other (Fig. 1a). In addition, secondary snapalysin:sermetstatin 
interaction sites are provided by sermetstatin helix α1, which 
interacts with the segment immediately downstream of the third 
zinc-binding residue of snapalysin (D93-G97), and Lβ4β5, which 
contacts the upper-rim strand of the peptidase on its non-primed 15 
side (Fig. 4). In particular, D47 of α1 approaches the main-chain 
amide nitrogen atoms of both Y95 and Q96 through its side chain. 
This causes the side chain of the latter residue to be pulled out 
towards bulk solvent in the complex. Finally, the frontal bulge 
segment above the primed-side of the active-site cleft of 20 
snapalysin, R51-D58, interacts with three short segments of the 
second sermetstatin molecule (chain D) within the heterotetramer 
at V23-T28, G37-P40, and F113 through four hydrogen bonds. 
Overall, this type of enzyme:inhibitor interaction is only distantly 
reminiscent of the inhibitory mode of tissue inhibitors of 25 
metalloproteinases on their target matrix metalloproteinases 28 
and of serralysin inhibitors on their cognate serralysin MPs 29. In 
these cases, N-terminal tails likewise bind in extended 
conformation but are found in the primed side of the cleft. 
Disulfide bonds in sermetstatin 30 
Disulfide bonds are a common feature of proteinase inhibitors 
that follow the standard mechanism, and we set out to assess the 
importance of the two that link the reactive-site loops to their 
subjacent scaffold helices by mutating the cysteine residues to 
serine. Wild-type sermetstatin, as well as mutants C31S+C46S and 35 
C69S+C99S, were incubated with either subtilisin or snapalysin. 
While the wild-type protein was not cleaved by either peptidase, 
mutant C69S+C99S, which was obtained with similar yields to the 
wild-type protein (see ESI), was completely degraded by 
subtilisin but not snapalysin. This suggested that the mutant 40 
inhibitor still had sufficient structural integrity to maintain its MP 
site functional but not to prevent the SP site from collapsing. By 
contrast, mutant C31S+C46S, which was obtained with a much 
lower yield than the wild-type, was readily degraded by both 
peptidases, strongly suggesting that this 45 
disulfide is essential for the overall 
structural conformation of the inhibitor. 
Accordingly, the disulfide bonds of 
sermetstatin are required for its double 
inhibitory activity because they reduce the 50 
conformational flexibility of the main 
chain around the reactive site and 
contribute to maintaining the overall 
scaffold in a competent conformation. 
Model for the ternary complex 55 
 All the structural information described 
has allowed us to construct a composite 
model of the ternary complex between 
subtilisin, sermetstatin, and snapalysin 
(Fig. 2d). This model shows a large 60 
inhibitory particle of maximal dimensions 
120x85x65Å, which is rather asymmetric and resembles a 
distorted cross with a large vertical bar arched by ~55º and a short 
horizontal bar, which intersect at an angle of ~75º. The model 
confirms the heterohexameric 2+2+2 arrangement found in 65 
solution (see ESI and Suppl. Fig. S1); no steric hindrance is 
observed upon peptidase binding to the distal inhibitory sites, and 
the proteinase surfaces are at least ~15Å apart. 
 In summary, sermetstatin is a genuine Janus-faced dimeric 
single-domain inhibitor which has evolved from single-site 70 
standard-mechanism SP inhibitors of family I16 to give a protein 
capable of simultaneous inhibition of SPs in general and a 
specific MP through distinct but compatible sites. 
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1. Experimental procedures 
 
Production and purification of sermetstatin – A synthetic gene coding for sermetstatin from 
Streptomyces caespitosus (UniProt database code Q9FDS0), also known as Streptomyces caespitosus 
neutral proteinase inhibitor 1, was purchased (GenScript) and cloned into a modified pET-32a vector 
between the BglII and HindIII restriction sites. This vector attaches an N-terminal thioredoxin-His6 
fusion construct followed by a tobacco-etch-virus (TEV) protease recognition site. Sermetstatin was 
produced by heterologous overexpression in Escherichia coli Origami2 (DE3) cells (Novagen). These 
were grown at 37°C in Luria-Bertani (LB) medium containing 100µg/ml ampicillin and 10µg/ml 
tetracycline, induced at an OD550 of 0.6 with isopropyl-β-D-thiogalactopyranoside (IPTG) to a final 
concentration of 0.25mM, and subsequently incubated overnight at 18°C. Cultures were centrifuged at 
7,000xg for 30min at 4°C. Pellets were washed twice with buffer A (50mM Tris-HCl, 500mM NaCl, 
pH8.0) and resuspended in the same buffer further containing 20mM imidazole and supplemented 
with EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics) and DNase I (Roche 
Diagnostics). Cells were lysed at 4ºC using a cell disrupter (Constant Systems) at a pressure of 
1.35Kbar, and the cell debris was removed by centrifugation at 50,000xg for 1h at 4°C. The 
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supernatant was filtered (0.22µm pore size; Millipore) and incubated with nickel-nitrilotriacetic acid 
(Ni-NTA) resin (Invitrogen) previously equilibrated with buffer A, 20mM imidazole. The protein was 
eluted using buffer A, 350mM imidazole. Subsequently, the sample was dialyzed overnight at room 
temperature against buffer B (50mM Tris-HCl, 150mM NaCl, 0.5mM oxidized glutathione [GSSG], 
3mM reduced glutathione [GSH], pH8.0) in the presence of His6-tagged TEV protease at an 
enzyme:substrate ratio of 1:50 (w/w). TEV cleavage leaves an extra glycine residue at the N-terminus 
of the protein (termed G-1; superscripted sermetstatin amino acid numbering hereafter corresponds to 
the mature protein without the 28-residue signal peptide [see UniProt Q9FDS0]). The digested sample 
was passed several times through Ni-NTA resin previously equilibrated with buffer A to remove His6-
containing molecules. The flow-through was collected, concentrated by ultrafiltration, and further 
purified by size-exclusion chromatography on a HiLoad 16/60 Superdex 75 column (GE Healthcare) 
previously equilibrated with buffer C (20mM Tris-HCl, 150mM NaCl, pH7.4). Previous column 
calibration revealed that the protein eluted as a dimer, and its identity and purity were assessed by 
mass spectrometry and 15% Tricine-SDS-PAGE stained with Coomassie blue. Ultrafiltration steps 
were performed with Vivaspin 15 and Vivaspin 500 filter devices with a 5-KDa cut-off (Sartorius 
Stedim Biotech). Protein concentration was determined by measuring the absorbance at 280 nm using 
a spectrophotometer (NanoDrop) and a calculated absorption coefficient Ε0.1% = 0.86.  
The present production system based on a fusion with thioredoxin and expression in Origami2 
cells, which is known to assist multi-disulfide proteins in folding correctly during intracellular 
biosynthesis, and further TEV-mediated removal of the fusion construct in selected concentrations of 
redox agents, yielded approx. 10mg of purified natively-folded protein per liter of cell culture. The 
selenomethionine variant of the protein was obtained in the same way as the wild-type except that 
cells were grown in minimal medium containing selenomethionine (Sigma) instead of methionine. A 
series of sermetstatin single- and double-point mutants, namely, H3E, H3R, Y33P+T34G, M71K, 
Y72V+F73Y, C31S+C46S, and C69S+C99S, was generated using the QuickChange Site-Directed 
Mutagenesis kit (Stratagene). All constructs were verified by DNA sequencing and mutant variants 
were produced and purified as for the wild-type protein, with comparable yields except for C31S+C46S, 
which was obtained with an approx. 100-fold lower yield. 
Production and purification of snapalysin – A synthetic gene coding for mature snapalysin 
from S. caespitosus, in which the N-terminal threonine had been replaced by methionine due to the 
cloning strategy, was purchased (GenScript) and cloned into a modified pET-28a vector between the 
NcoI and XhoI restriction sites. This vector attaches an N-terminal His6 fusion tag, followed by a TEV 
protease recognition site. The protein was overproduced as inclusion bodies in E. coli BL21 (DE3) 
cells, which were grown at 37°C in LB medium supplemented with 30µg/ml kanamycin, induced at an 
OD550 of 0.8 with 1mM IPTG, and grown for a further 5h at 37°C. After centrifugation at 7,000xg for 
30min at 4°C, the pellet was resuspended in buffer D (PBS, 1% Triton X-100, pH7.4) containing 
EDTA-free protease inhibitor cocktail tablets and DNase I. Cells were lysed at 4ºC using a cell 
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disrupter at a pressure of 1.9Kbar and incubated for 30min at 37°C. The inclusion bodies were 
recovered by centrifugation at 7,000xg for 30min at 4°C and washed twice with buffer D, resuspended 
in buffer A, 8M urea, and incubated for 5h at room temperature under vigorous shaking. The sample 
was centrifuged at 50,000xg for 1h at 20°C, the supernatant was incubated with Ni-NTA resin 
previously equilibrated with buffer A, 8M urea, and the fusion protein was eluted using buffer E 
(50mM sodium phosphate, 250mM NaCl, 8M urea, pH4.0). The sample was dialyzed overnight at 
room temperature against buffer A plus 0.5mM GSSG, 1mM GSH, 10mM CaCl2, 1mM ZnS04, and 
0.4M L-arginine, and subsequently dialyzed overnight at 4°C against buffer C. The N-terminal 
extension of the snapalysin construct was removed by autolytic cleavage as determined by Edman 
degradation, yielding an N-terminal segment Q-3+G-2+P-1+M1 (italicized snapalysin amino acids 
subscripted numbering correspond to UniProt P56406 plus the additional N-terminal tag residues and 
the T1M mutation; although this is a secreted protein, the signal-peptide sequence is unknown and the 
database entry corresponds to the authentic protein purified from culture supernatants of S. 
caespitosus). The protein was concentrated by ultrafiltration, and further purified by size-exclusion 
chromatography on a Superdex 75 10/300 column previously equilibrated with buffer C. Protein 
identity and purity were assessed by Edman degradation and 15% Tricine-SDS-PAGE stained with 
Coomassie blue. Ultrafiltration steps were performed with Vivaspin 15 and Vivaspin 500 filter devices 
with 5-KDa cut-off. Protein concentration was determined by measuring the absorbance at 280nm 
using a NanoDrop spectrophotometer and a calculated absorption coefficient Ε0.1% = 1.7. This 
procedure yielded functional snapalysin at very low concentration (approx. 50µg per liter of cell 
culture), which was used for activity assays (see below).  
In vitro activation studies of prosnapalysin – To study the transition between latent and mature 
snapalysins, a synthetic gene encompassing the chemical sequence of prosnapalysin from 
Streptomyces coelicor—the sequence of the pro-peptide of the zymogen from S. caespitosus is not 
known—lacking the 29-residue signal peptide and with the N-terminal alanine replaced with 
methionine (A30M; numbering in regular characters according to UniProt P0A3Z7) due to the cloning 
strategy, was purchased (GenScript) and cloned into the aforementioned modified pET-28a vector 
using the NcoI and XhoI restriction sites. Prosnapalysin active-site mutant E164A was obtained using 
the QuickChange Site-Directed Mutagenesis kit and verified by DNA sequencing. Both proteins were 
overproduced in E. coli BL21 (DE3) cells, which were grown at 37°C in LB medium supplemented 
with kanamycin to a final concentration of 30µg/ml. Thereafter, cells were induced at an OD550 of 0.8 
with IPTG to a final concentration of 1mM and grown for a further 5h at 37°C. After centrifugation at 
7,000xg for 30min at 4°C, the pellet was resuspended in buffer D containing EDTA-free protease 
inhibitor cocktail tablets and DNase I. Cells were lysed at 4ºC using a cell disrupter at a pressure of 1.9 
Kbar and incubated for 30min at 37°C. The resulting inclusion bodies were recovered by 
centrifugation at 7,000xg for 30min at 4°C and washed twice with buffer D, resuspended in buffer A, 
8M urea, and incubated for 5h at room temperature under vigorous shaking. The sample was 
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centrifuged at 50,000xg for 1h at 20°C, the supernatant was incubated with Ni-NTA resin previously 
equilibrated with buffer A, 8M urea, and the fusion protein was eluted using buffer E. The sample was 
then first dialyzed overnight at room temperature against buffer A plus 0.5mM GSSG, 1mM GSH, 
10mM CaCl2, 1mM ZnS04, and 0.4M L-arginine, and then dialyzed overnight at 4°C against buffer C. 
The fusion tag of prosnapalysin mutant E164A was cleaved overnight at room temperature in buffer C, 
0.5mM GSSG, 3mM GSH by incubation with TEV proteinase (enzyme:substrate ratio of 1:50 [w/w]). 
Proteins were concentrated by ultrafiltration, and further purified by size-exclusion chromatography 
on a HiLoad 16/60 Superdex 75 column previously equilibrated with buffer C. The final yield for the 
wild-type and the mutant was approx. 2mg and 5mg, respectively, per liter of cell culture. Protein 
identity and purity were assessed by Edman degradation and 15% Tricine-SDS-PAGE stained with 
Coomassie blue. Cleavage of wild-type and mutant prosnapalysin was monitored by mass 
spectrometry, SDS-PAGE and Edman degradation of electro-blotted bands onto an Immun-Blot PVDF 
membrane (BioRad). Ultrafiltration steps were performed with Vivaspin 15 and Vivaspin 500 filter 
devices of 5-KDa cut-off. Protein concentration was determined by measuring the absorbance at 280 
nm using a NanoDrop and a calculated absorption coefficient Ε0.1% = 1.38 for both variants. 
Proteolytic and inhibition assays – Ulilysin from Methanosarcina acetivorans, aeruginolysin 
from Pseudomonas aeruginosa, and fragilysin-3 from Bacteroides fragilis were produced and purified 
as previously described 2-5. The vector coding for aeruginolysin was a kind gift from Ulrich Baumann 
(University of Cologne, Germany). Astacin and matrix metalloproteinases-1, -3, and -13 were kindly 
provided by Walter Stöcker (Johannes Gutenberg-University of Mainz, Germany) and Hideaki Nagase 
(Imperial College London, UK), respectively. Proteolytic activity of ADAM-17 was kindly measured 
by Jordi Malapeira and Joaquin Arribas (Vall d'Hebron Institute of Oncology, Spain) using the 
substrate vasorin in a cell-based assay as previously published 6. Subtilisin Carlsberg from Bacillus 
licheniformis, thermolysin from Bacillus thermoproteolyticus, bovine pancreatic trypsin, bovine 
pancreatic chymotrypsin, porcine pancreatic elastase, and fungal proteinase K from Engyodontium 
album were purchased from Sigma. Evident proteolytic activity of all these proteinases and 
recombinant snapalysin from S. caespitosus was measured at 1µM enzyme concentration in buffer C 
at 37°C with the fluorescein conjugates BODIPY FL casein and DQ gelatin (65µg/ml, Invitrogen) as 
substrates by using microplates (Nunc) and a microplate fluorimeter (FLx800, BioTek) at λex = 485nm 
/ λem = 528nm. Increasing amounts of purified wild-type and mutant variants of sermetstatin were 
added to the assays to determine inhibition (see Suppl. Table S2). In addition, inhibition of wild-type 
sermetstatin against subtilisin and snapalysin was tested by using the substrates succinyl-A-A-P-F-p-
nitroanilide (Sigma) and aminobenzoyl-V-K-F-Y-D-I-K(2,4-dinitrophenylamino), respectively,—
kindly provided by Jean-Louis Reymond (University of Berne, Switzerland)—in buffer C, and the 
associated apparent inhibition constants (Ki) were derived from a Dixon plot. 
Cleavage of sermetstatin mutants –Wild-type sermetstatin, as well as mutants C31S+C46S and 
C69S+C99S (at 0.5mg/ml in 20mM Tris-HCl, 50mM NaCl, pH7.4), were incubated with equimolar 
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amounts of either subtilisin or snapalysin overnight at room temperature. The reactions were then 
assessed for cleavage in a Bruker Autoflex III mass spectrometer. Each sample was mixed at a 1:1 
ratio (v/v) with a matrix solution of sinapinic acid (10mg/ml, Sigma) dissolved in 30% acetonitrile and 
0.1% trifluoroacetic acid, and subsequently spotted onto the plate using the dried-droplet method. 
Mass spectra were acquired in linear mode geometry with >1,000 laser shots and using a protein 
mixture ranging from 5 KDa to 17.5 KDa  (Protein Calibration Standard I, Bruker) as a calibrator.  
Complex formation and purification – Commercial subtilisin Carlsberg from B. licheniformis 
was purified by size-exclusion chromatography on a HiLoad 16/60 Superdex 75 column previously 
equilibrated with buffer C. The subtilisin:sermetstatin complex was formed by incubation of 
equimolar amounts of purified wild-type inhibitor and protease, and it eluted as a 2+2 heterotetramer 
in calibrated size-exclusion chromatography. The complex was concentrated by ultrafiltration up to 
5.5mg/ml using Vivaspin 15 and Vivaspin 500 filter devices of 30-KDa cut-off. Protein concentration 
was determined by measuring the absorbance at 280nm using a NanoDrop spectrophotometer and a 
calculated absorption coefficient Ε0.1% = 0.89. To produce sufficient amounts of snapalysin for 
structural studies, inclusion bodies of snapalysin were obtained and purified as described above. Next, 
unfolded snapalysin dissolved in buffer E was diluted 1:9 against buffer A, 0.55mM GSSG, 1.1mM 
GSH, 11mM CaCl2, 1.1mM ZnS04, 0.44M L-arginine and an equimolar amount of wild-type 
sermetstatin. The sample was incubated for 4h at 4°C and dialyzed overnight at 4°C against buffer C. 
The snapalysin:sermetstatin complex was concentrated by ultrafiltration, and further purified by size-
exclusion chromatography on a HiLoad 16/60 Superdex 75 column previously equilibrated with buffer 
C and calibrated, which revealed that the complex was a 2+2 heterotetramer in solution. The sample 
was dialyzed overnight at 4°C against buffer F (20mM Tris-HCl, 1M NaCl, pH7.4) and concentrated 
by ultrafiltration to 4.5mg/ml using Vivaspin 15 and Vivaspin 500 filter devices of 10-KDa cut-off. 
The protein concentration was determined by measuring the absorbance at 280nm using a NanoDrop 
spectrophotometer and a calculated absorption coefficient Ε0.1% = 1.32. Finally, the ternary complex 
between subtilisin, sermetstatin, and snapalysin was obtained by adding an equimolar amount of 
subtilisin to the snapalysin:sermetstatin complex. A further size-exclusion chromatography step in a 
calibrated Superdex 200 10/300 column previously equilibrated with buffer C revealed that the 
quaternary arrangement in solution was a 2+2+2 heterohexamer (see Suppl. Fig. S4). The complex 
was concentrated by ultrafiltration to 7.5mg/ml with Vivaspin 15 and Vivaspin 500 filter devices of 
10-KDa cut-off. Protein concentration was determined by measuring the absorbance at 280nm using a 
NanoDrop spectrophotometer and a calculated absorption coefficient Ε0.1% = 1.1. 
Crystallization and X-ray diffraction data collection – Crystallization assays of sermetstatin, its 
two binary complexes with snapalysin and subtilisin, and the ternary complex with both peptidases 
were carried out by the sitting-drop vapor diffusion method. Reservoir solutions were prepared by a 
Tecan robot, and 200-nl crystallization drops, equivolumetric in protein solution and reservoir 
solution, were dispensed on 96x2-well MRC plates (Innovadyne) by a Cartesian nanodrop robot 
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(Genomic Solutions) at the IBMB/IRB joint High-Throughput Automated Crystallography Platform. 
Crystallization plates were stored in Bruker steady-temperature crystal farms at 4ºC and 20°C. 
Successful hits were scaled up to the microliter range with 24-well Cryschem crystallization dishes 
(Hampton Research) whenever possible. 
The best crystals of wild-type and selenomethionine-derivatized sermetstatin appeared at 20°C 
with protein solution (10mg/ml in buffer C) and 100mM sodium citrate dihydrate, 200mM ammonium 
acetate, 10% (w/v) PEG3,350, pH5.6 as reservoir solution in microliter drops. The best crystals of the 
subtilisin:sermetstatin complex were obtained at 4°C with protein solution (5.5mg/ml in buffer C) and 
100mM cacodylate, 200mM zinc acetate dihydrate, 10% (v/v) 2-propanol, pH6.5 as reservoir solution 
from microliter drops. Suitable crystals of the snapalysin:sermetstatin complex were obtained from 
200-nanoliter drops at 20°C with protein solution (4.5mg/ml in buffer F) and 100mM HEPES, 200mM 
magnesium chloride, 15.0% (v/v) ethanol, pH7.5 as reservoir solution. No suitable crystals of the 
ternary complex could be obtained despite extensive trials. Crystals were cryo-protected by successive 
passages through reservoir solutions containing increasing amounts of glycerol (up to 25-30% [v/v]). 
Complete diffraction datasets were collected at 100K from liquid-N2 flash-cryo-cooled crystals 
(Oxford Cryosystems 700 series cryostream) on MarCCD (beam line ID23-2, native sermetstatin, 
snapalysin:sermetstatin complex) and ADSC Q315R CCD (ID29, sermetstatin selenomethionine 
derivative; and ID23-1, subtilisin:sermetstatin complex) detectors at the European Synchrotron 
Radiation Facility (ESRF, Grenoble, France) within the Block Allocation Group “BAG Barcelona”. 
Crystals of both native and selenomethionine-derivatized sermetstatin were trigonal, with one 
molecule per asymmetric unit (VM = 3.2Å3/Da; 62% solvent content). Crystals of 
subtilisin:sermetstatin were monoclinic, with two complexes per asymmetric unit (VM = 3.6Å3/Da; 
65% solvent content). Crystals of snapalysin:sermetstatin were orthorhombic with six complexes per 
asymmetric unit (VM = 2.9Å3/Da; 58% solvent content). Diffraction data were integrated, scaled, 
merged, and reduced with programs XDS 7, XSCALE, and SCALA 8 within the CCP4 suite 9 (see 
Suppl. Table S3).  
Structure solution and refinement – All attempts to solve the structure of unbound sermetstatin 
by Patterson search 10 using the coordinates of the related Streptomyces subtilisin inhibitor (SSI; 
Protein Data Bank [PDB] access code 3SSI; 11) from Streptomyces albogriseolus as a searching model 
failed despite a sequence identity of 43%. Therefore, the structure was solved by single-wavelength 
anomalous diffraction using a selenomethionine derivative and program SHELXD 12. Diffraction data 
of a crystal collected at the selenium absorption-peak wavelength, as inferred from a XANES 
fluorescence scan, enabled the program to identify all three selenium sites of the monomer present in 
the asymmetric unit. Subsequent phasing with SHELXE 12 resolved the twofold ambiguity intrinsic to 
a SAD experiment due to the difference in the values of the pseudo-free correlation coefficient of the 
two possible hands, which confirmed P3121 as the correct space group. An initial model was built with 
program COOT 13 and refined against the selenomethionine dataset with program REFMAC5 14. The 
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resulting partial model was used to determine the native structure by Patterson-search methods with 
program PHASER 15. One unambiguous hit was found, which yielded Z-scores for the rotation and 
translation functions of 20.4 and 46.0, respectively. Subsequently, manual model building with COOT 
and TURBO-Frodo 16 alternated with crystallographic refinement (including TLS refinement) with 
programs REFMAC5 and BUSTER/TNT 17 until completion of the model (Suppl. Table S3). The final 
model of sermetstatin comprised residues G-1+S1-F113 (chain A) plus ligands and solvent molecules 
(see Suppl. Table S3). The dimeric quaternary arrangement observed in solution (see above) was 
likewise found in the crystal formed by a crystallographic twofold axis.  
The structure of the subtilisin:sermetstatin complex was solved by Patterson-search methods 
with program PHASER using the co-ordinates of subtilisin Carlsberg from B. licheniformis (Protein 
Data Bank [PDB] access code 1SBC; 18) and sermetstatin as search models. Two unambiguous hits 
were found for each of the two molecules, which showed Z-scores for the rotation/translation 
functions of 20.8/22.8 and 18.7/46.2 (subtilisin) and 6.0/36.2 and 6.8/44.5 (sermetstatin). The 
quaternary arrangement in the crystal asymmetric unit is a 2+2 heterotetramer (chains A-D). Model 
building and refinement—with automatic non-crystallographic symmetry restraints—proceeded as 
before (Suppl. Table S3). The final model contained residues A1-Q275 (subscripted subtilisin residue 
numbers according to the mature enzyme sequence; see UniProt P00780) and two calcium ions (Ca999 
and Ca998) for the two subtilisin moieties (chains A and C), G-1+S1-F113 for sermetstatin chain B, and 
G4-F113 for sermetstatin chain D plus ligands and solvent molecules (see Suppl. Table S3).  
The structure of the snapalysin:sermetstatin complex was likewise solved by Patterson search 
using the coordinates of S. caespitosus snapalysin (PDB 1KUH; 19) and sermetstatin. Due to the 
presence of 12 molecules in the asymmetric unit in total, searches had to be split into two steps: first, 
four copies of each protein were searched for independently, enabling us to identify two complexes 
showing the same relative arrangement between proteinase and inhibitor. In a second search, one such 
complex was used as a search model, which yielded six solutions arranged as three 2+2 
heterotetramers (chains A-D, E-H, I-L), with Z-scores for the respective rotation/translation functions 
of 6.7/15.3, 8.1/26.2, 7.3/29.8, 8.8/35.9, 5.5/37.8, and 6.6/35.7. Model building and refinement—with 
automatic non-crystallographic symmetry restraints—proceeded as before (Suppl. Table S3). The final 
model contained snapalysin residues G-2+P-1+M1-G132 in chains A, C, and I; residues P-1+M1-G132 in 
chains G and K; and residues M1-G132 in chain E. In addition, sermetstatin chains spanned residues S1-
F113 (chains B and L), A2-F113 (chain F), S1-A62+L67-F113 (chain D), S1-L60+L67-F113 (chain H), and S1-
P65+V68-F113 (chain J). Further ligands and solvent molecules completed the model (see Suppl. Table 
S3). Due to the distinct packing environments of the molecules within the crystal, chains E and K were 
overall less well-defined by electron density that the other ten chains; this is indicated by the 
significantly higher average thermal displacement parameters for their protein parts (76.0 and 90.3Å2, 
respectively) than the remaining molecules (44.8-64.5Å2). 
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A composite model of the ternary 2+2+2 complex between subtilisin, sermetstatin, and 
snapalysin was obtained with TURBO-Frodo starting from the subtilisin:sermetstatin complex after 
superposition of the dimeric inhibitor moieties of the binary complexes. Only the N-terminal segment, 
Lβ2β3, and segment β1-Lβ1β2-β2 had to be slightly remodeled to match the conformation found in 
the snapalysin:sermetstatin complex. These segments were subjected to geometric refinement with 
TURBO-Frodo. 
Miscellaneous –Figures were prepared with programs TURBO-Frodo and CHIMERA 20. 
Interaction surfaces (taken as half of the surface area buried at a complex interface) and close contacts 
(<4Å) were determined with CNS 21. Structure similarities were investigated with DALI 22. Model 
validation was performed with MOLPROBITY 23 and the WHATCHECK routine of WHATIF 24. 
Sequence alignments and phylogenetic calculations were performed with MULTALIN 25. The final 
coordinates of sermetstatin, the subtilisin:sermetstatin complex, and the snapalysin:sermetstatin 
complex have been deposited with the PDB at www.pdb.org (access codes 4HWX, 4HX2, and 4HX3). 
The model of the ternary complex is available from the authors upon request. 
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4. Supplemental Tables 
Suppl. Table S1. Janus-faced single-domain inhibitors with at least two reactive sites. 
Family (MEROPS) Inhibitor name Source UniProt code Class of targets Targets PDB code Ref. 
Kunitz (I3) 
 
 
 
 
Bowman-Birk (I12) 
 
 
 
 
 
 
 
 
 
 
 
Clitocypin (I48) 
Macrocypin (I85) 
 
Others 
ApKTI 
PKPI 
API 
PPI 
WCI 
MSTI 
sBBI 
LCTI 
BTCI 
HGI-III 
CLTI 
A-II 
TcTI 
I-2B 
II-4 
LBI 
GBI 
Clitocypin 
Macrocypin 1 
 
Trypsin inhibitor 
Adenanthera pavonina 
Solanum tuberosum 
Sagittaria sagittifolia 
Carica papaya 
Psophocarpus tetragonolobus 
Medicago scutellata 
Glycine max 
Lens culinaris 
Vigna unguiculata 
Dolichos biflorus 
Canavalia lineata 
Arachis hypogaea 
Amburana acreana 
Triticum aestivum 
Triticum aestivum 
Phaseolus lunatus 
Phaseolus vulgaris 
Clitocybe nebularis 
Macrolepiota procera 
 
Trichosanthes kirilowii 
P09941 
Q66LL2 
Q7M1P4 
P80691 
P10822 
P80321 
P01055 
Q8W4Y8 
P17734 
Q9S9E3 
Q7M1Q0 
P01066 
P83284 
P09863 
P09864 
P01056 
P01060 
Q3Y9I4 
B9V973 
 
P01069 
SP a (and CP a) 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
CP 
CP (and SP) 
 
SP 
Trypsin and papain (very weakly) 
Trypsin and chymotrypsin 
Trypsin, chymotrypsin and kallikrein  
Trypsin 
Chymotrypsin 
Trypsin 
Trypsin and chymotrypsin 
Trypsin and chymotrypsin 
Trypsin and chymotrypsin 
Trypsin and chymotrypsin 
Trypsin and chymotrypsin 
Trypsin and chymotrypsin 
Trypsin, plasmin and chymotrypsin 
Trypsin 
Trypsin 
Trypsin and chymotrypsin 
Trypsin, chymotrypsin and elastase 
Papain and cathepsins L, V, S and K 
Papain and cathepsins L, V, S and K 
(Macrocypin 4 inhibits trypsin weakly) 
Trypsin 
- 
3TC2 
3E8L b 
3S8K, 3S8J 
2WBC 
2ILN b 
1PI2, 1D6R b 
2AIH 
2G81 c, 2OT6 
- 
- 
Not deposited 
- 
- 
- 
1H34 
- 
3H6R, 3H6S d 
3H6Q 
 
- 
26 
27, 28 
29, 30 
31 
32 
33 
34, 35 
36 
37, 38 
39 
40 
41, 42 
43 
44 
44 
45, 46 
47 
48 
48 
 
49 
a  SP and CP stand for serine and cysteine proteases, respectively. b  Complex with two molecules of trypsin. c  Complex with trypsin. d  Complex with cathepsin V. 
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Suppl. Table S2. Inhibitory activity of sermetstatin variants. 
  Wild-type Y33P+T34G M71K Y72V+F73Y 
Protease Molar ratio 
(Inh./Enz.) 
Inhibitory 
activity (%) 
Inhibitory 
activity (%) 
Inhibitory 
activity (%) 
Inhibitory 
activity (%) 
 
Metallopeptidases 
Snapalysin 
 
Astacin 
Ulilysin 
Aeruginolysin  
Thermolysin 
Fragilysin 
ADAM-17 a 
MMP-1,-3,-13 a 
 
Serine proteinases 
Subtilisin 
Trypsin 
Chymotrypsin 
Elastase 
Proteinase K 
 
 
 
 
1 
10 
100 
100 
100 
100 
100 
- 
100 
 
 
1 
10 
10 
10 
1 
10 
 
 
99 
100 
0 
0 
0 
0 
0 
NI b 
0 
 
 
95 
21 
69 
68 
82 
100 
 
 
1 
52 
0 
0 
0 
0 
0 
- 
0 
 
 
95 
29 
47 
67 
75 
100 
 
 
90 
100 
0 
0 
0 
0 
0 
- 
0 
 
 
24 
53 
29 
0 
5 
36 
 
 
96 
100 
0 
0 
0 
0 
0 
- 
0 
 
 
93 
31 
56 
62 
77 
100 
 
Values as mean of three independent measurements, SD within ±5. a ADAM stands for a disintegrin and 
metalloprotease, MMP for matrix metalloproteinase. b NI, no inhibition at 4 µM inhibitor concentration in 
a cell-based assay. 
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Suppl. Table S3. Crystallographic data. 
 Sermetstatin Subtilisin:sermetstatin Snapalysin:sermetstatin 
 
Dataset 
 
Space group 
Cell constants (a, b, c, in Å; β in º if ≠90) 
Wavelength (Å) 
No. of measurements / unique reflections 
Resolution range (Å) (outermost shell) b 
Completeness [/ Anom. completeness] (%) 
Rmerge c 
Rr.i.m. (= Rmeas) c [/ Rp.i.m. c] 
Average intensity (<[<I> / σ(<I>)]>) 
B-Factor (Wilson) (Å2) / Aver. multiplicity 
Resolution range used for refinement (Å) 
No. of reflections used (test set) 
Crystallographic Rfactor (free Rfactor) c 
No. of protein atoms / solvent molecules / 
     neutral ligands 
     ionic ligands 
 
Rmsd from target values 
     bonds (Å)  /  angles (°) 
     Average B-factors for protein atoms (Å2) 
Main-chain conformational angle analysis d
 
     Residues in  
     favored regions / outliers / all residues 
 
Native 
 
P3121 
71.04, 71.04, 52.40 
0.8726 
134,041 / 12,234 
39.9 – 1.90 (2.00 – 1.90) 
99.3 (98.9) 
0.038 (0.596) 
0.040 (0.625) / 0.012 (0.185) 
40.3 (4.9) 
32.7 / 11.0 (11.1) 
∞ – 1.90 
11,844 (479) 
0.187 (0.214) 
834  /  126 / 
1 glycerol 
3 CH3COO- 
 
 
0.010  /  1.14 
40.4 
 
 
109 / 1 / 112 
 
Selenomethionine 
 (absorption peak) a 
P3121 
70.81, 70.81, 52.25 
0.9791 
218,877 / 10,514 
26.4 – 2.00 (2.11 – 2.00) 
99.8 (100.0) / 99.7 (100.0) 
0.074 (0.757) 
0.077 (0.793) / 0.023 (0.235) 
35.4 (8.0) 
29.5 / 20.8 (21.8) 
 
Native 
 
C2 
183.97, 83.62, 77.62; 110.78 
0.9763 
312,908 / 52,346 
48.6 – 2.25 (2.37– 2.25) 
99.9 (99.7) 
0.097 (0.751) 
0.106 (0.842) / 0.043 (0.368) 
13.2 (2.0) 
41.9 / 6.0 (4.9) 
∞ – 2.25 
51,487 (797) 
0.177 (0.217) 
5,483  /  305 / 
1 diglycerol, 3 2-propanol, 2 glycerol  
4 Ca2+, 2 Zn2+, 2 K+, 1 Cl-, 
1 (CH3)2AsOO-, 1 CH3COO-, 1 PO43-  
 
0.010  /  1.12 
51.1 
 
 
744 / 1 / 764 
 
Native 
 
P212121 
116.54, 121.81, 130.67 
0.8726 
211,0198 / 51,602 
89.1 – 2.70 (2.77– 2.70) 
99.4 (95.8) 
0.091 (0.704) 
0.105 (0.845)  
14.7 (1.9) 
51.9 / 4.1 (3.2) 
∞ – 2.70 
50,699 (782) 
0.195 (0.242) 
11,043  /  275 / 
2 glycerol 
6 Zn2+ 
 
 
0.010  /  1.06 
58.2 
 
 
1,406 / 2 / 1,436 
 
a Friedel-mates were treated as separate reflections. b Values in parentheses refer to the outermost resolution shell.
 
c For definitions, see Table 1 in 50. d According to MOLPROBITY 51. 
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5. Supplemental Figures 
 
 
 
Suppl. Figure S1 –Size-exclusion chromatography of the ternary complex. (a) The complex between subtilisin, 
sermetstatin and snapalysin was loaded onto a Superdex 200 10/300 column. The complex eluted after 13.3ml, 
which corresponds to 102KDa and reveals the formation of a 2+2+2 heterohexamer in solution (theoretical mass 
107.8KDa). The column was calibrated with the following protein standards: aldolase (158KDa; elution after 
12.5ml), conalbumin (75KDa; 13.9ml), ovalbumin (43KDa; 14.8ml), and cytochrome C (12.4KDa; 17.8ml). The 
presence of the three molecules (subtilisin 27KDa, snapalysin 15KDa, and sermetstatin 12KDa) was further 
confirmed by SDS-PAGE (see inset) after trichloroacetic acid-precipitation of the collected sample. (b) The 
isolated inhibitor and the binary and ternary complexes were loaded onto a Superdex 75 10/300 column for 
comparison. The sermetstatin eluted after 12.2ml (1+1), the snapalysin:sermetstatin complex after 11.6ml (2+2), 
the subtilisin:sermetstatin complex after 10.0ml (2+2), and the ternary complex after 9.2ml (2+2+2).  
